Mean values of generic and SLE-adapted cardiovascular risk scores at baseline of 124 patients with SLE with or without vascular ultrasound-confirmed atherosclerosis and with or without progression of atherosclerosis
| All patients (N=124) | With plaques at baseline* (n=30) | No plaques at baseline (n=94) | P value† | With new plaques (n=26) | Without new plaques (n=98) | P value‡ | |
| SCORE (%) | 0.67±0.8 | 0.98±0.7 | 0.54±0.8 | 0.022 | 1.01±0.9 | 0.52±0.7 | 0.014 |
| mSCORE (%) | 1±1.2 | 1.46±1.1 | 0.8±1.2 | 0.022 | 1.52±1.4 | 0.8±0.9 | 0.014 |
| FRS (%) | 5.2±4.5 | 8.2±5.4 | 4.2±3.7 | <0.001 | 9±5.8 | 4.2±3.5 | <0.001 |
| mFRS (%) | 10.5±9.1 | 10.8±2.0 | 8.5±7.4 | <0.001 | 18±11.6 | 8.4±7.0 | <0.001 |
| QRISK3 (%) | 9.1±7.1 | 14±7.8 | 7.5±6.0 | <0.001 | 13.5±7.6 | 7.9±6.4 | <0.001 |
| PCRE (%) | 3.7±5.0 | 6.1±7.2 | 2.6±3 | 0.002 | 5±6.8 | 3.2±4 | 0.114 |
| Globorisk (%) | 6.7±5.6 | 9.0±6.5 | 5.8±4.9 | 0.014 | 9.9±7.8 | 5.3±3.5 | <0.001 |
| PROCAM score (points) | 23.3±13.0 | 33.8±10 | 19.9±12 | <0.001 | 30±10.2 | 21.5±13.0 | 0.003 |
*Carotid plaques in 25 patients, femoral plaques in 19 patients and plaques at both arterial sites in 14 patients.
†Comparison between patients with or without atherosclerotic plaques at baseline.
‡Comparison between patients with or without new atherosclerotic plaques at follow-up.
FRS, Framingham Risk Score; mFRS, modified Framingham Risk Score; mSCORE, modified Systematic Coronary Risk Evaluation; PCRE, Pooled Cohort Risk Equation; PROCAM, Prospective Cardiovascular Münster; QRISK3, QRESEARCH Risk Estimator V.3; SCORE, Systematic Coronary Risk Evaluation.